Loading...
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population
Waddell, Tom Pillai, Manon Armitage, Kate Graham, Donna M Moran, M. Dilleen, M. Holmes, S. Śleszyńska-Dopiera, E. Hawkins, Robert
Waddell, Tom
Pillai, Manon
Armitage, Kate
Graham, Donna M
Moran, M.
Dilleen, M.
Holmes, S.
Śleszyńska-Dopiera, E.
Hawkins, Robert
Citations
Altmetric:
Abstract
Aim: Renal cell carcinoma (RCC) is the seventh commonest cancer in the UK, where first-line (1L) sunitinib and second-line (2L) axitinib are treatment options.Methods: Retrospective, non-interventional data from the Christie NHS Foundation Trust (Manchester, UK). The primary end point was median progression-free survival (mPFS).Results: For 1L sunitinib (n = 622) and 2L axitinib (n = 121), mPFS (95% CI) was 8.4 (7.6, 9.9) and 6.2 (4.9, 9.3) months, respectively. In 1L, Karnofsky performance status, lactate dehydrogenase (LDH), neutrophils, hemoglobin, time from diagnosis to treatment and age were predictors (p < 0.05) of PFS. In 2L, LDH and platelets were predictors of PFS (p < 0.05).Conclusion: Sunitinib and axitinib were effective treatments for RCC. PFS predictors varied between 1L and 2L; LDH was a predictor for both.Clinical Trial Registration: NCT04033991 (ClinicalTrials.gov).
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Article
Citation
Waddell T, Pillai M, Armitage K, Graham DM, Moran M, Dilleen M, et al. Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population. Future oncology (London, England). 2024;20(33):2547-58. PubMed PMID: 39382446. Pubmed Central PMCID: PMC11534105. Epub 2024/10/09. eng.